| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABBVIE INC | 11,656,800 | 721,672,000 | 33.91% | ||
| 2 | REYNOLDS AMERICAN INC | 9,322,463 | 502,760,000 | 23.62% | ||
| 3 | PROTHENA CORP PLC | 10,304,751 | 360,254,000 | 16.93% | ||
| 4 | ALKERMES PLC SHS | 7,535,533 | 325,686,000 | 15.30% | ||
| 5 | Theravance Biopharma Inc | 8,733,637 | 198,166,000 | 9.31% | ||
| 6 | NORTHWEST BIOTHERAPEUTICS INC | 25,915,937 | 15,065,000 | 0.71% | ||
| 7 | BIOGEN INC | 20,000 | 4,836,000 | 0.23% |
Portfolio data is normalized using SEC Form 13F filings, including the Restatement filing (0001213900-17-005684, filed 2017.05.22).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
